EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015 (Infliximab Biosimilar)
November 16, 2015 06:05 ET
|
EPIRUS Biopharmaceuticals, Inc.
Readiness for on-time initiation of pivotal global registration study with completion of manufacturing process lockBOW015 remains on track for 2017 global filingBOW015 targets large market opportunity...
EPIRUS Biopharmaceuticals Reports Third Quarter 2015 Financial Results & Provides Business Update
November 16, 2015 06:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals Appoints Industry Veteran Vincent E. Aurentz as Chief Business Officer
November 10, 2015 08:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 10, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals Joins Biosimilars Forum to Help Educate Patients and Healthcare Providers on Importance of Biosimilars
November 05, 2015 08:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 05, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals to Release Third Quarter 2015 Financial Results and Provide Business Update
October 29, 2015 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Oct. 29, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through Acquisition of Bioceros
September 09, 2015 06:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
Combined companies’ product pipeline targets reference biologics with sales of $29 billion in 2014Pipeline expanded to include biosimilars to Soliris®, STELARA® and SIMPONI® Capabilities...
Patient Safeguards Needed for Biosimilar Development
August 08, 2014 17:46 ET
|
RetireSafe
MISSION, KS--(Marketwired - Aug 8, 2014) - (Family Features) Thanks to a provision in the Patient Protection and Affordable Care Act, efforts are underway to streamline licensing for medications...
Global Biosimilars Market
October 24, 2013 07:46 ET
|
Research and Markets
Dublin, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/wlm2kp/global)
has announced the addition of the "Global
Biosimilars Market - Products,...
AVID Bioservices Highlights Antibody Engineering, Expression and Bioassay Expertise at AACR
April 02, 2012 16:00 ET
|
Avid Bioservices
TUSTIN, CA--(Marketwire - Apr 2, 2012) - Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today presented data at the Annual Meeting of the American Association of...
Colon Cancer Alliance Welcomes FDA's Biosimilars Guidance, Encourages Agency to Keep Patient Safety "First and Foremost"
February 14, 2012 16:14 ET
|
Colon Cancer Alliance
WASHINGTON, Feb. 14, 2012 (GLOBE NEWSWIRE) -- Colon Cancer Alliance CEO Andrew Spiegel yesterday showed support for the Food and Drug Administration's (FDA) draft guidelines for an American...